Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
University of California, San Francisco
Genentech, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Nammi Therapeutics Inc
Jazz Pharmaceuticals
EMD Serono
National Cancer Institute (NCI)
SystImmune Inc.
GI Innovation, Inc.
Merck Sharp & Dohme LLC
Mayo Clinic
Neonc Technologies, Inc.
Genmab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Myeloid Therapeutics
Daiichi Sankyo
Jonsson Comprehensive Cancer Center
Avacta Life Sciences Ltd
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Innate Pharma
Dren Bio
Mayo Clinic
Tanabe Pharma America, Inc.
RenJi Hospital
Incyte Corporation
Pfizer
Tempest Therapeutics
Nurix Therapeutics, Inc.
Pfizer
Exelixis
Incyte Corporation
Jonsson Comprehensive Cancer Center
Xencor, Inc.
Institut Claudius Regaud
NuCana plc
University of Virginia
Incyte Corporation
NextPoint Therapeutics, Inc.
UNICANCER
OncoC4, Inc.
Monopar Therapeutics
Monopar Therapeutics
Klus Pharma Inc.
SOLTI Breast Cancer Research Group
Checkpoint Therapeutics, Inc.
RAPT Therapeutics, Inc.
Cybrexa Therapeutics